UniView Aggregates and Displays Patient Data From Multiple Devices to
Minimize Clinician Cognitive Overload and Maximize Patient Safety
IRVINE, Calif.--(BUSINESS WIRE)--Apr. 2, 2018--
Masimo (NASDAQ:
MASI) announced today the release of UniView™, an integrated display of
real-time data and alarms from multiple Masimo and third-party devices,
designed to reduce clinician cognitive overload and improve patient
safety. UniView promotes data sharing and team coordination among
multiple clinicians.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180402005238/en/
Masimo UniView™ (Photo: Business Wire)
In operating rooms (ORs), in intensive care units (ICUs), and in other
areas which involve multiple clinical disciplines, clinicians are often
unable to simultaneously view data from all of the various medical
devices in use, resulting in information that remains siloed among, for
example, anesthesiologists, surgeons, and nurses. In addition, the
plethora of displays and user interfaces adds to cognitive overload that
can cause clinician burnout and suboptimal patient care.
UniView solves these problems by bringing together data from a variety
of sources – such as patient monitors, ventilators, anesthesia gas
machines, and IV pumps – and providing a supplementary display for them,
clearly organized, on one or more large, central monitors, so that all
clinicians can simultaneously view and act upon the same, comprehensive
real-time patient status and historical trends. Visual alarm indicators,
relayed from the connected devices, help clinicians recognize patient
distress and target areas for immediate focus. UniView is suitable for
any area where comprehensive, logically organized, and timely data are
key to supporting good clinical care.
UniView also provides tailored, use-case-specific screen layouts which
optimize the presentation of advanced and integrated parameters, trend
data, and waveforms for a variety of clinical scenarios, making it a
versatile solution in many environments. For example:
-
In Overview layout, view monitoring data from all connected
point-of-care and therapeutic devices including waveforms and alarms,
for an overview of patient status.
-
In Hemodynamics layout, view trend data for noninvasive
hemoglobin (SpHb®), pleth variability index (PVi®),
and pulse rate to aid in visualizing patient status over time.
-
In Oxygenation layout, view ventilator waveforms alongside
noninvasive trended hemoglobin (SpHb) and oxygen saturation (SpO2)
to monitor a patient’s oxygenation status.
-
In Sedation layout, view high-fidelity EEG waveforms, patient
state index (PSi), and anesthesia machine data to monitor a patient’s
sedation.
In addition, hospitals will be able customize the view as preferred and
even take advantage of individual customization using Masimo MyView™
technology.
Joe Kiani, Founder and CEO of Masimo, said, “We are answering
clinicians’ calls for logical, clinically transformational cockpits for
the collaborative ORs and ICUs of the future. UniView is a great example
of Masimo’s ongoing commitment to automating patient care, whether it’s
making pulse oximeters accurate when you need that accuracy most,
creating new noninvasive monitoring technologies such as SpHb, or in
this case, unsiloing data, enhancing connectivity, and communicating
patient data as effectively and efficiently as possible, so that
clinicians can focus more on their patients. We look forward to
introducing additional enhancements soon – helping to bring automation
and connectivity to the next level.”
UniView builds on the success of Kite™, which projects data from Root®
on a larger screen, by aggregating data from all of the connected
devices in a room, including third-party ones, so that a supplemental
display of all monitoring data can be viewed by all. UniView works in
conjunction with Masimo Iris Gateway™ and Patient SafetyNet™*
connectivity platforms. Complementing UniView, the recently announced
Masimo Replica™ allows clinicians to view similar monitoring data for
multiple patients, as well as view and respond to alarms and alerts, all
from a smart phone, regardless of location.
@MasimoInnovates |
#Masimo
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo UniView™, Iris Gateway™, and Patient SafetyNet™.
These forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo UniView, Iris Gateway, and
Patient SafetyNet, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique advantages; as
well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005238/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com